熱門資訊> 正文
索诺玛制药公司根据美国化妆品法注册HOCI面部喷雾剂
2025-10-07 20:49
- Sonoma Pharmaceuticals (NASDAQ:SNOA) has registered its Microcyn-based facial spray and manufacturing facility under the FDA’s Modernization of Cosmetics Regulation Act of 2022.
- The registration allows Sonoma to commercialize HOCl-based products as cosmetics in the U.S., expanding its regulatory footprint.
- Sonoma’s facility was already FDA-registered for medical device manufacturing, supporting a broad portfolio in wound care, dermatology, eye care, podiatry, and animal health.
- The MoCRA listing positions Sonoma to enter the fast-growing U.S. skincare market, projected to reach $40B by 2030.
- The company highlights its patented hypochlorous acid technology as a clean, effective solution for common skin conditions, aligning with rising demand for science-backed skincare.
- SNOA shares down 5.5% premarket on Tuesday.
- Source: Press release
More on Sonoma Pharmaceuticals
- Seeking Alpha’s Quant Rating on Sonoma Pharmaceuticals
- Historical earnings data for Sonoma Pharmaceuticals
- Financial information for Sonoma Pharmaceuticals
推薦文章
Rocket Lab宣佈與美國太空發展局達成價值8.16億美元的協議
「港股英偉達」來了！壁仞科技今起招股，一手入場費3959.54港元
年終盤點 | 46年來最猛黃金牛市！3倍、4倍、5倍牛股頻出，2026黃金會繼續瘋狂嗎？
一周財經日曆 | 美聯儲新主席「呼之欲出」！特朗普下周或提前公佈；年末新股上市潮！卧安機器人、英矽智能等6只新股招股中
年終盤點 | 26年投資展望！美股有哪些經濟大事？
年終盤點 | 2025年港美股十大飆升ETF：年內暴漲620%！Palantir多頭槓桿ETF成年度黑馬
年終盤點 | 2025年港股牛股、妖股、熊股名單出爐！這家公司飆升超33倍后跌落神壇
年終盤點 | 美股七巨頭從「集體狂飆」到「殘酷分化」！誰能在2026年繼續坐莊？
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
